Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial Lancet Oncol
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma Future Oncol
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study CANCER-AM CANCER SOC
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia J Hematol Oncol
A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression Nat Commun